University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Pavithra Viswanath, PhD

Pavithra Viswanath, PhD

Associate Professor, Dept. of Radiology and Biomedical Imaging, UCSF

Cancer Center Program Memberships

Neurologic Oncology

Research Summary

Dr. Pavithra Viswanath is an Associate Professor in the Department of Radiology and Biomedical Imaging at UCSF. She graduated with a Ph D in Biochemistry from the Indian Institute of Science in Bangalore, India. The overall vision of her research is to harness insights from tumor genetics, epigenetics and biology to drive the preclinical development of novel, metabolic imaging biomarkers that will ultimately benefit patients by enabling the non-invasive assessment of tumor burden and response to therapy. In parallel, she will pinpoint metabolic vulnerabilities that can be exploited for the development of novel therapeutic and theranostic agents. Her long-term goal is to work with clinical and translational colleagues at UCSF and beyond to enable clinical translation of the imaging methods, therapeutics and theranostics that come out of her preclinical studies.

Education

St. Xavier’s college, Goa University, Goa, India, BSc, 2000, Microbiology
Indian Institute of Science, Bangalore, India, MS, 2003, Biochemistry
Indian Institute of Science, Bangalore, India, PhD, 2007, Biochemistry

Honors & Awards

  • Career Enhancement Program Award, UCSF Brain Tumor Center SPORE, 2017
  • Career Enhancement Program Award, UCSF Brain Tumor Center SPORE, 2018
  • Inaugural Women in Neuro-oncology Basic/Translational Science Research Award, Society for Neuro-oncology, 2019
  • Margaret Hart Surbeck Travel Award, Dept. of Radiology and Biomedical Imaging, UCSF

Selected Publications

  1. Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Delos Santos R, Viswanath P, Costello JF, Pieper RO, Ronen SM. Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment. Cancer Res. 2020 Sep 21.
    View on PubMed
  2. Molloy AR, Najac C, Viswanath P, Lakhani A, Subramani E, Batsios G, Radoul M, Gillespie AM, Pieper RO, Ronen SM. MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics. 2020; 10(19):8757-8770.
    View on PubMed
  3. Batsios G, Najac C, Cao P, Viswanath P, Subramani E, Saito Y, Gillespie AM, Yoshihara HAI, Larson P, Sando S, Ronen SM. In vivo detection of ?-glutamyl-transferase up-regulation in glioma using hyperpolarized ?-glutamyl-[1-13C]glycine. Sci Rep. 2020 Apr 10; 10(1):6244.
    View on PubMed
  4. Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci Rep. 2019 07 19; 9(1):10521.
    View on PubMed
  5. Najac C, Radoul M, Le Page LM, Batsios G, Subramani E, Viswanath P, Gillespie AM, Ronen SM. In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. Sci Rep. 2019 03 04; 9(1):3402.
    View on PubMed
  6. Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM. HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI. NMR Biomed. 2019 02; 32(2):e4044.
    View on PubMed
  7. Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab. 2018; 6:3.
    View on PubMed
  8. Viswanath P, Radoul M, Izquierdo-Garcia JL, Ong WQ, Luchman HA, Cairncross JG, Huang B, Pieper RO, Phillips JJ, Ronen SM. 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. Cancer Res. 2018 05 01; 78(9):2290-2304.
    View on PubMed
  9. Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10743-10748.
    View on PubMed
  10. Viswanath P, Morayya S, Rautela N, Sinha A. Development of a rapid and reliable assay for in vitro determination of compound cidality against the asexual stages of Plasmodium falciparum. Acta Parasitol. 2016 Dec 01; 61(4):828-835.
    View on PubMed
  11. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 11 15; 76(22):6680-6689.
    View on PubMed
  12. Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO. Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res. 2016 10; 14(10):976-983.
    View on PubMed
  13. Chaumeil MM, Radoul M, Najac C, Eriksson P, Viswanath P, Blough MD, Chesnelong C, Luchman HA, Cairncross JG, Ronen SM. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin. 2016; 12:180-9.
    View on PubMed
  14. Viswanath P, Najac C, Izquierdo-Garcia JL, Pankov A, Hong C, Eriksson P, Costello JF, Pieper RO, Ronen SM. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 07; 7(23):34942-55.
    View on PubMed
  15. Viswanath P, Chaumeil MM, Ronen SM. Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Front Oncol. 2016; 6:60.
    View on PubMed
  16. Viswanath P, Ronen SM. Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1. Mol Cell Oncol. 2016 Apr 01; 3(2):e1077922.
    View on PubMed
  17. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Cai L, Radoul M, Chaumeil MM, Blough M, Luchman HA, Weiss S, Cairncross JG, Phillips JJ, Pieper RO, Ronen SM. IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015 Aug 01; 75(15):2999-3009.
    View on PubMed
  18. Hameed P S, Solapure S, Patil V, Henrich PP, Magistrado PA, Bharath S, Murugan K, Viswanath P, Puttur J, Srivastava A, Bellale E, Panduga V, Shanbag G, Awasthy D, Landge S, Morayya S, Koushik K, Saralaya R, Raichurkar A, Rautela N, Roy Choudhury N, Ambady A, Nandishaiah R, Reddy J, Prabhakar KR, Menasinakai S, Rudrapatna S, Chatterji M, Jiménez-Díaz MB, Martínez MS, Sanz LM, Coburn-Flynn O, Fidock DA, Lukens AK, Wirth DF, Bandodkar B, Mukherjee K, McLaughlin RE, Waterson D, Rosenbrier-Ribeiro L, Hickling K, Balasubramanian V, Warner P, Hosagrahara V, Dudley A, Iyer PS, Narayanan S, Kavanagh S, Sambandamurthy VK. Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nat Commun. 2015 Mar 31; 6:6715.
    View on PubMed
  19. Izquierdo-Garcia JL, Viswanath P, Eriksson P, Chaumeil MM, Pieper RO, Phillips JJ, Ronen SM. Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015; 10(2):e0118781.
    View on PubMed
  20. Hameed P S, Chinnapattu M, Shanbag G, Manjrekar P, Koushik K, Raichurkar A, Patil V, Jatheendranath S, Rudrapatna SS, Barde SP, Rautela N, Awasthy D, Morayya S, Narayan C, Kavanagh S, Saralaya R, Bharath S, Viswanath P, Mukherjee K, Bandodkar B, Srivastava A, Panduga V, Reddy J, Prabhakar KR, Sinha A, Jiménez-Díaz MB, Martínez MS, Angulo-Barturen I, Ferrer S, Sanz LM, Gamo FJ, Duffy S, Avery VM, Magistrado PA, Lukens AK, Wirth DF, Waterson D, Balasubramanian V, Iyer PS, Narayanan S, Hosagrahara V, Sambandamurthy VK, Ramachandran S. Aminoazabenzimidazoles, a novel class of orally active antimalarial agents. J Med Chem. 2014 Jul 10; 57(13):5702-13.
    View on PubMed

Go to UCSF Profiles, powered by CTSI